Company intelligence / Profile preview
Ho Chai Kung
- Ownership
- Private
- Development stage
- Other
Overview
Ho Chai Kung is an established OTC brand in Hong Kong with strong market position in the analgesics category. The brand reported net profit of HK$38.7 million on sales of HK$85.2 million in FY15, with a net profit margin of 45.4%. As of FY2025, Ho Chai Kung delivered strong growth of 43.2% in branded medicines sales revenue, driven by sustained market momentum and expanded market penetration through targeted marketing initiatives.
- Therapeutic areas
- NeurologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Ho Chai Kung.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ho Chai Kung.